US: Cipla recalls over 400 cartons of cancer drug
What's the story
Cipla USA, a subsidiary of Indian pharmaceutical giant Cipla, has announced the recall of over 400 cartons of its anti-cancer drug Nilotinib Capsules. The move comes after the capsules were found to have failed tablet/capsule specifications due to a manufacturing issue. The US Food and Drug Administration (FDA) flagged this as a voluntary Class III recall, indicating that it is not likely to cause any adverse health consequences.
Recall specifics
The affected lots include a total of 435 cartons
The recalled Nilotinib Capsules come in two strengths: 150mg and 200mg. The affected lots include a total of 435 cartons, with 271 from one lot and 164 from another. Cipla USA, Inc voluntarily initiated this Class III recall on February 18, after discovering that the capsules didn't meet required specifications during manufacturing.
Drug function
Nilotinib is used to treat certain types of cancer
Nilotinib is a targeted therapy used to treat certain types of cancer by blocking the action of an abnormal protein that signals cancer cells to multiply. This mechanism helps stop or slow the spread of these cells. The recall is classified as a voluntary Class III recall, but it highlights the importance of stringent manufacturing standards in ensuring patient safety and treatment effectiveness.
Industry impact
India has the largest number of USFDA-compliant pharmaceutical plants
India has the largest number of USFDA-compliant pharmaceutical plants outside the US. Indian companies supply a major chunk of drugs to American consumers, with four out of 10 prescriptions filled in the US in 2022 coming from Indian firms. This recall by Cipla USA highlights the need for continuous quality assurance processes in global supply chains to maintain trust and safety standards.